A Single Vaccination with an Improved Nonspreading Rift Valley Fever Virus Vaccine Provides Sterile Immunity in Lambs

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Oreshkova, Nadia ^a,b   van Keulen, Lucien ^a   Kant, Jet ^a   Moormann, Rob J M ^a,b   Kortekaas, Jeroen ^a  

^a WAGENINGEN UNIVERSITY   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; NEUTRALIZING ANTIBODY; RIFT VALLEY FEVER VACCINE; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; LAMB; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RIFT VALLEY FEVER; RIFT VALLEY FEVER BUNYAVIRUS; VACCINATION; VIREMIA; VIRUS IMMUNITY; VIRUS NEUTRALIZATION; ANIMAL; BAGG ALBINO MOUSE; CD4+ T LYMPHOCYTE; CELL LINE; CELLULAR IMMUNITY; HAMSTER; HUMAN; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; PREGNANCY; RIFT VALLEY FEVER VIRUS; SHEEP; VIRUS GENOME;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; CRICETINAE; FEMALE; GENOME, VIRAL; HUMANS; IMMUNITY, CELLULAR; IMMUNOLOGIC MEMORY; MICE; MICE, INBRED BALB C; PREGNANCY; RIFT VALLEY FEVER; RIFT VALLEY FEVER VIRUS; SHEEP; VACCINATION; VIRAL VACCINES;

EID: 84886043555     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0077461     Document Type: Article

References (64)

1. Gerdes GH, (2004) Rift Valley fever. Rev Sci Tech 23: 613-623.
2. Sissoko D, Giry C, Gabrie P, Tarantola A, Pettinelli F, et al. (2009) Rift Valley fever, Mayotte, 2007-2008. Emerg Infect Dis 15: 568-570.
3. Roger M, Girard S, Faharoudine A, Halifa M, Bouloy M, et al. (2011) Rift valley fever in ruminants, Republic of Comoros, 2009. Emerg Infect Dis 17: 1319-1320.
4. CDC (2000) Outbreak of Rift Valley fever- Saudi Arabia, August-October, 2000. MMWR Morb Mortal Wkly Rep 49: 905-908.
5. CDC (2000) Outbreak of Rift Valley Fever Virus- Yemen, August-October 2000. MMWR Morb Mortal Wkly Rep 49: 1065-1066.
6. Coetzer JA, (1977) The pathology of Rift Valley fever. I. Lesions occurring in natural cases in new-born lambs. Onderstepoort J Vet Res 44: 205-211.
7. Coetzer JA, (1982) The pathology of Rift Valley fever. II. Lesions occurring in field cases in adult cattle, calves and aborted foetuses. Onderstepoort J Vet Res 49: 11-17.
8. Easterday BC, (1965) Rift valley fever. Adv Vet Sci 10: 65-127.
9. Madani TA, Al-Mazrou YY, Al-Jeffri MH, Mishkhas AA, Al-Rabeah AM, et al. (2003) Rift Valley fever epidemic in Saudi Arabia: epidemiological, clinical, and laboratory characteristics. Clin Infect Dis 37: 1084-1092.
10. Laughlin LW, Meegan JM, Strausbaugh LJ, Morens DM, Watten RH, (1979) Epidemic Rift Valley fever in Egypt: observations of the spectrum of human illness. Trans R Soc Trop Med Hyg 73: 630-633.
11. Pepin M, Bouloy M, Bird BH, Kemp A, Paweska J, (2010) Rift Valley fever virus(Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention. Vet Res 41: 61.
12. Elliott RM (1996) The Bunyaviridae. New York & London: Plenum Press.
13. Billecocq A, Spiegel M, Vialat P, Kohl A, Weber F, et al. (2004) NSs protein of Rift Valley fever virus blocks interferon production by inhibiting host gene transcription. J Virol 78: 9798-9806.
14. Bouloy M, Janzen C, Vialat P, Khun H, Pavlovic J, et al. (2001) Genetic evidence for an interferon-antagonistic function of rift valley fever virus nonstructural protein NSs. J Virol 75: 1371-1377.
15. Ikegami T, Narayanan K, Won S, Kamitani W, Peters CJ, et al. (2009) Rift Valley fever virus NSs protein promotes post-transcriptional downregulation of protein kinase PKR and inhibits eIF2alpha phosphorylation. PLoS Pathog 5: e1000287.
16. Ikegami T, Narayanan K, Won S, Kamitani W, Peters CJ, et al. (2009) Dual functions of Rift Valley fever virus NSs protein: inhibition of host mRNA transcription and post-transcriptional downregulation of protein kinase PKR. Ann N Y Acad Sci 1171Suppl 1: E75-85.
17. Habjan M, Pichlmair A, Elliott RM, Overby AK, Glatter T, et al. (2009) NSs protein of rift valley fever virus induces the specific degradation of the double-stranded RNA-dependent protein kinase. J Virol 83: 4365-4375.
18. Kakach LT, Wasmoen TL, Collett MS, (1988) Rift Valley fever virus M segment: use of recombinant vaccinia viruses to study Phlebovirus gene expression. J Virol 62: 826-833.
19. Won SY, Ikegami T, Peters CJ, Makino S, (2007) NSm protein of Rift Valley fever virus suppresses virus-induced apoptosis. Journal of Virology 81: 13335-13345.
20. Moutailler S, Krida G, Schaffner F, Vazeille M, Failloux AB, (2008) Potential vectors of Rift Valley fever virus in the Mediterranean region. Vector Borne Zoonotic Dis 8: 749-753.
21. Chevalier V, Pepin M, Plee L, Lancelot R, (2010) Rift Valley fever-a threat for Europe? Euro Surveill 15: 19506.
22. Gale P, Brouwer A, Ramnial V, Kelly L, Kosmider R, et al. (2010) Assessing the impact of climate change on vector-borne viruses in the EU through the elicitation of expert opinion. Epidemiol Infect 138: 214-225.
23. Dufour B, Moutou F, Hattenberger AM, Rodhain F, (2008) Global change: impact, management, risk approach and health measures-the case of Europe. Rev Sci Tech 27: 529-550.
24. Kasari TR, Carr DA, Lynn TV, Weaver JT, (2008) Evaluation of pathways for release of Rift Valley fever virus into domestic ruminant livestock, ruminant wildlife, and human populations in the continental United States. J Am Vet Med Assoc 232: 514-529.
25. Beer M, Conraths FJ, van der Poel WH, (2013) 'Schmallenberg virus'-a novel orthobunyavirus emerging in Europe. Epidemiol Infect 141: 1-8.
26. Botros B, Omar A, Elian K, Mohamed G, Soliman A, et al. (2006) Adverse response of non-indigenous cattle of European breeds to live attenuated Smithburn Rift Valley fever vaccine. J Med Virol 78: 787-791.
27. Kamal SA, (2009) Pathological studies on postvaccinal reactions of Rift Valley fever in goats. Virol J 6: 94.
28. Barnard BJ, Botha MJ, (1977) An inactivated rift valley fever vaccine. J S Afr Vet Assoc 48: 45-48.
29. Dungu B, Louw I, Lubisi A, Hunter P, von Teichman BF, et al. (2010) Evaluation of the efficacy and safety of the Rift Valley Fever Clone 13 vaccine in sheep. Vaccine 28: 4581-4587.
30. von Teichman B, Engelbrecht A, Zulu G, Dungu B, Pardini A, et al. (2011) Safety and efficacy of Rift Valley fever Smithburn and Clone 13 vaccines in calves. Vaccine 29: 5771-5777.
31. Caplen H, Peters CJ, Bishop DH, (1985) Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development. J Gen Virol 66 (Pt 10): 2271-2277.
32. Saluzzo JF, Smith JF, (1990) Use of reassortant viruses to map attenuating and temperature-sensitive mutations of the Rift Valley fever virus MP-12 vaccine. Vaccine 8: 369-375.
33. Morrill JC, Jennings GB, Caplen H, Turell MJ, Johnson AJ, et al. (1987) Pathogenicity and immunogenicity of a mutagen-attenuated Rift Valley fever virus immunogen in pregnant ewes. Am J Vet Res 48: 1042-1047.
34. Morrill JC, Carpenter L, Taylor D, Ramsburg HH, Quance J, et al. (1991) Further Evaluation of a Mutagen-Attenuated Rift-Valley Fever Vaccine in Sheep. Vaccine 9: 35-41.
35. Morrill JC, Mebus CA, Peters CJ, (1997) Safety and efficacy of a mutagen-attenuated Rift Valley fever virus vaccine in cattle. Am J Vet Res 58: 1104-1109.
36. Morrill JC, Mebus CA, Peters CJ, (1997) Safety of a mutagen-attenuated Rift Valley fever virus vaccine in fetal and neonatal bovids. Am J Vet Res 58: 1110-1114.
37. Hunter P, Erasmus BJ, Vorster JH, (2002) Teratogenicity of a mutagenised Rift Valley fever virus (MVP 12) in sheep. Onderstepoort J Vet Res 69: 95-98.
38. Morrill JC, Laughlin RC, Lokugamage N, Pugh R, Sbrana E, et al. (2013) Safety and immunogenicity of recombinant Rift Valley fever MP-12 vaccine candidates in sheep. Vaccine 31: 559-565.
39. Morrill JC, Laughlin RC, Lokugamage N, Wu J, Pugh R, et al. (2013) Immunogenicity of a recombinant Rift Valley fever MP-12-NSm deletion vaccine candidate in calves. Vaccine.
40. Bird BH, Maartens LH, Campbell S, Erasmus BJ, Erickson BR, et al. (2011) Rift Valley fever virus vaccine lacking the NSs and NSm genes is safe, nonteratogenic, and confers protection from viremia, pyrexia, and abortion following challenge in adult and pregnant sheep. J Virol 85: 12901-12909.
41. Bouloy M, Flick R, (2009) Reverse genetics technology for Rift Valley fever virus: current and future applications for the development of therapeutics and vaccines. Antiviral Res 84: 101-118.
42. Boshra H, Lorenzo G, Busquets N, Brun A, (2011) Rift Valley Fever: Recent Insights into Pathogenesis and Prevention. J Virol 85: 6098-6105.
43. Ikegami T, Makino S, (2009) Rift valley fever vaccines. Vaccine 27Suppl 4: D69-72.
44. Indran SV, Ikegami T, (2012) Novel approaches to develop Rift Valley fever vaccines. Front Cell Infect Microbiol 2: 131.
45. Kortekaas J, Oreshkova N, Cobos-Jimenez V, Vloet RP, Potgieter CA, et al. (2011) Creation of a nonspreading Rift Valley fever virus. J Virol 85: 12622-12630.
46. Dodd KA, Bird BH, Metcalfe MG, Nichol ST, Albarino CG, (2012) Single-dose immunization with virus replicon particles confers rapid robust protection against Rift Valley fever virus challenge. J Virol 86: 4204-4212.
47. Kortekaas J, Antonis AF, Kant J, Vloet RP, Vogel A, et al. (2012) Efficacy of three candidate Rift Valley fever vaccines in sheep. Vaccine 30: 3423-3429.
48. Antonis AFG, Kortekaas JA, Kant J, Vloet RPM, Vogel-Brink A, et al. (2013) Vertical transmission of Rift Valley fever virus without detectable maternal viremia. Vector-Borne and Zoonotic Diseases.
49. Barnard BJ, (1979) Rift Valley fever vaccine-antibody and immune response in cattle to a live and an inactivated vaccine. J S Afr Vet Assoc 50: 155-157.
50. Niwa H, Yamamura K, Miyazaki J, (1991) Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108: 193-199.
51. Keegan K, Collett MS, (1986) Use of Bacterial Expression Cloning to Define the Amino-Acid-Sequences of Antigenic Determinants on the G2-Glycoprotein of Rift-Valley Fever Virus. J Virol 58: 263-270.
52. Cole GA, (2005) Interferon-gamma ELISPOT assay for the quantitative measurement of antigen-specific murine CD8+ T-cells. Methods Mol Biol 302: 191-204.
53. Bhardwaj N, Heise MT, Ross TM, (2010) Vaccination with DNA plasmids expressing Gn coupled to C3d or alphavirus replicons expressing gn protects mice against Rift Valley fever virus. PLoS Negl Trop Dis 4: e725.
54. Gambotto A, Dworacki G, Cicinnati V, Kenniston T, Steitz J, et al. (2000) Immunogenicity of enhanced green fluorescent protein (EGFP) in BALB/c mice: identification of an H2-Kd-restricted CTL epitope. Gene Ther 7: 2036-2040.
55. Tao P, Luo M, Pan R, Ling D, Zhou S, et al. (2009) Enhanced protective immunity against H5N1 influenza virus challenge by vaccination with DNA expressing a chimeric hemagglutinin in combination with an MHC class I-restricted epitope of nucleoprotein in mice. Antiviral Res 81: 253-260.
56. de Boer SM, Kortekaas J, Antonis AF, Kant J, van Oploo JL, et al. (2010) Rift Valley fever virus subunit vaccines confer complete protection against a lethal virus challenge. Vaccine 28: 2330-2339.
57. Kärber G, (1931) Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie 162: 480-483.
58. Spearman C, (1908) The method of 'right and wrong cases' ('constant stimuli') without gauss's formulae. British Journal of Psychology, 1904-1920 2: 227-242.
59. Kortekaas J, Dekker A, de Boer SM, Weerdmeester K, Vloet RP, et al. (2010) Intramuscular inoculation of calves with an experimental Newcastle disease virus-based vector vaccine elicits neutralizing antibodies against Rift Valley fever virus. Vaccine 28: 2271-2276.
60. Gerrard SR, Nichol ST, (2002) Characterization of the Golgi retention motif of Rift Valley fever virus G(N) glycoprotein. J Virol 76: 12200-12210.
61. Gorchakov R, Volkova E, Yun N, Petrakova O, Linde NS, et al. (2007) Comparative analysis of the alphavirus-based vectors expressing Rift Valley fever virus glycoproteins. Virology 366: 212-225.
62. Burgdorf S, Kurts C, (2008) Endocytosis mechanisms and the cell biology of antigen presentation. Curr Opin Immunol 20: 89-95.
63. Villadangos JA, (2001) Presentation of antigens by MHC class II molecules: getting the most out of them. Mol Immunol 38: 329-346.
64. Lozach PY, Kuhbacher A, Meier R, Mancini R, Bitto D, et al. (2011) DC-SIGN as a receptor for phleboviruses. Cell Host Microbe 10: 75-88.